Year None20232022202120202019201820172016 Date Latest Press Release May 11, 2023 Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update May 3, 2023 Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) April 13, 2023 Eiger BioPharmaceuticals Strengthens Management Team with New Appointments March 16, 2023 Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update February 8, 2023 New England Journal of Medicine Publishes Positive Phase 3 TOGETHER Results with Peginterferon Lambda in COVID-19 December 15, 2022 Eiger BioPharmaceuticals Announces Leadership Change December 8, 2022 Eiger Announces Both Lonafarnib-based Treatments in Pivotal Phase 3 D-LIVR Trial in Hepatitis Delta Virus (HDV) Achieved Statistical Significance Against Placebo in Composite Primary Endpoint December 7, 2022 Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 D-LIVR Study Results of Lonafarnib-based Treatments in Hepatitis Delta Virus (HDV) on Thursday, December 8, 2022 November 8, 2022 Eiger BioPharmaceuticals to Participate in Upcoming Investor Conferences November 3, 2022 Eiger BioPharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
